Taylor J M, Griffith K A, Sandler H M
Department of Biostatistics, University of Michigan, Ann Arbor, MI 48104, USA.
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1212-9. doi: 10.1016/s0360-3016(01)01571-1.
The American Society for Therapeutic Radiology and Oncology (ASTRO) published a consensus panel definition of biochemical failure following radiation therapy for prostate cancer. In this paper, we develop a series of alternative definitions of biochemical failure. Using data from 688 patients, we evaluated the sensitivity and specificity of the various definitions, with respect to a defined "clinically meaningful" outcome.
The ASTRO definition of biochemical failure requires 3 consecutive rises in prostate-specific antigen (PSA). We considered several modifications to the standard definition: to require PSA rises of a certain magnitude, to consider 2 instead of 3 rises, to require the final PSA value to be greater than a fixed cutoff level, and to define biochemical failure based on the slope of PSA over 1, 1.5, or 2 years. A clinically meaningful failure is defined as local recurrence, distant metastases, initiation of unplanned hormonal therapy, unplanned radical prostatectomy, or a PSA > 25 later than 6 months after radiation.
Requiring the final PSA in a series of consecutive rises to be larger than 1.5 ng/mL increased the specificity of biochemical failure. For a fixed specificity, defining biochemical failure based on 2 consecutive rises, or the slope over the last year, could increase the sensitivity by up to approximately 20%, compared to the ASTRO definition. Using a rule based on the slope over the previous year or 2 rises leads to a slightly earlier detection of biochemical failure than does the ASTRO definition. Even with the best rule, only approximately 20% of true failures are biochemically detected more than 1 year before the clinically meaningful event time.
There is potential for improvement in the ASTRO consensus definition of biochemical failure. Further research is needed, in studies with long follow-up times, to evaluate the relationship between various definitions of biochemical failure and true clinical outcome.
美国放射肿瘤学会(ASTRO)发布了前列腺癌放射治疗后生化失败的共识小组定义。在本文中,我们制定了一系列生化失败的替代定义。利用688名患者的数据,我们针对一个明确的“具有临床意义的”结果,评估了各种定义的敏感性和特异性。
ASTRO对生化失败的定义要求前列腺特异性抗原(PSA)连续3次升高。我们考虑了对标准定义的几种修改:要求PSA升高达到一定幅度,考虑2次而非3次升高,要求最终PSA值大于固定的临界水平,以及根据PSA在1年、1.5年或2年期间的斜率来定义生化失败。具有临床意义的失败被定义为局部复发、远处转移、开始非计划的激素治疗、非计划的根治性前列腺切除术,或放疗后6个月后PSA>25。
要求一系列连续升高中的最终PSA大于1.5 ng/mL可提高生化失败的特异性。对于固定的特异性,与ASTRO定义相比,基于连续2次升高或过去一年的斜率来定义生化失败,可将敏感性提高约20%。使用基于前一年斜率或2次升高的规则,比ASTRO定义能更早地检测出生化失败。即使采用最佳规则,在具有临床意义的事件发生时间前1年以上,通过生化检测出的真正失败病例也仅约占20%。
ASTRO关于生化失败的共识定义有改进的潜力。需要在长期随访研究中进一步开展研究,以评估生化失败的各种定义与真实临床结果之间的关系。